You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Parkinson Disease: How Disease Progression Impacts Care

  • Authors: Michael S. Okun, MD; Daniel O. Claassen, MD; Daniel E. Kremens, MD, JD, FAAN
  • CME / CE Released: 10/11/2022
  • Valid for credit through: 10/11/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    Nurses - 1.00 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for neurologists, nurse practitioners (NPs), and nurses involved in the care of patients with Parkinson disease.

The goal of this activity is that learners will be better able to effectively select a pharmacotherapy or device-based approach for the management of PD.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Appropriate pharmacotherapies to consider at different stages of Parkinson disease 
    • Factors involved in the identification of patients with Parkinson disease who are candidates for on-demand therapies  
    • Clinical data on the use of on-demand therapies for the management of Parkinson disease  
    • Factors involved in the identification of patients who are candidates for device-based therapies for the management of Parkinson disease  
    • Factors that differentiate device-based approaches for the management of Parkinson disease   
  • Have greater competence related to
    • Selecting an appropriate pharmacotherapy for the management of Parkinson disease


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Session Chair

  • Michael S. Okun, MD

    Professor and Chair of Neurology
    University of Florida Health
    Director, Norman Fixel Institute for Neurological Diseases
    Gainesville, Florida

    Disclosures

    Michael S. Okun, MD, has no relevant financial relationships.

Faculty

  • Daniel O. Claassen, MD

    Professor of Neurology
    Vanderbilt University Medical Center
    Nashville, Tennessee

    Disclosures

    Daniel O. Claassen, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Alterity; Annexon; Novartis; Spark; Teva Neuroscience
    Research funding from: AbbVie; Acadia; Genentech; Prilenia; Roche; Vaccinex

  • Daniel E. Kremens, MD, JD, FAAN

    Associate Professor of Neurology
    Vice-Chair of Education
    Co-Director, Comprehensive Parkinson’s Disease and Movement Disorders Center
    Farber Institute for Neuroscience
    Sidney Kimmel Medical College
    Thomas Jefferson University Hospitals
    Philadelphia, Pennsylvania

    Disclosures

    Daniel E. Kremens, MD, JD, FAAN, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Acadia; Acorda; Adamas; Allergan; Amneal; Avion; Brittania; Kyowa; Merz; Neurocrine; Sunovion; Supernus; Teva; US WorldMeds
    Speaker or member of speakers bureau for: Acadia; Acorda; Adamas; Amneal; Kyowa; Neurocrine; Suniovion; Supernus; Teva; US WorldMeds
    Research funding from: Revance; Voyager Therapeutics

Editors

  • Meg Monday

    Senior Director, Content Development, Medscape, LLC 

    Disclosures

    Meg Monday has no relevant financial relationships. 

  • Lisette Arnaud-Hevi, PhD

    Medical Education Director, Medscape, LLC 

    Disclosures

    Lisette Arnaud-Hevi, PhD, has no relevant financial relationships.  

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC 

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships. 

Peer Reviewer:

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.00  AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

    For Nurses

  • Awarded 1.00 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Parkinson Disease: How Disease Progression Impacts Care

Authors: Michael S. Okun, MD; Daniel O. Claassen, MD; Daniel E. Kremens, MD, JD, FAANFaculty and Disclosures

CME / CE Released: 10/11/2022

Valid for credit through: 10/11/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Pharmacotherapeutic Recommendations Across the Disease Course in Parkinson Disease: Advanced Parkinson Disease Review

When to start, and what to start with. Dr Claassen discusses the various therapeutic approaches and combinations as PD progresses.
Daniel O. Claassen, MD

Spotlight On: On-Demand Therapies for the Management of Parkinson Disease

Dr Kremens discusses how on-demand therapies for PD fit within the treatment paradigm of PD.
Daniel E. Kremens, MD, JD, FAAN

Spotlight On: Surgery and Devices for the Management of Parkinson Disease

Dr Okun presents the latest data for the continuous management of PD.
Michael S. Okun, MD